LAWRENCE, Mass., June 1 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems in-center business has completed development of the new Streamline blood tubing sets for use on the B. Braun Dialog(R) and Dialog Plus hemodialysis systems in the U.S. In connection with this development, NxStage and B. Braun have agreed to extend their supply agreement under which NxStage will supply B. Braun with the new Streamline sets and B. Braun will provide sales, marketing, and clinical support to its U.S. customers.
"The launch of Streamline for the B. Braun machines broadens our relationship and extends the value of our product portfolio to B. Braun's Renal Therapies Division giving patients and providers greater access to NxStage's high quality, value-added in-center offerings," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "Streamline's ability to improve patient clearances and reduce cost is yet another example of NxStage's ability to innovate and bring value in the form of both clinical benefits and operational savings."
"We are pleased to broaden our relationship with NxStage by offering the unique Streamline technology to our dialysis customers," stated Samuel Amory, Vice President, B. Braun Medical Renal Therapies Division. "We look forward to leveraging Streamline's benefits with our state-of-the-art Dialog hemodialysis system and growing our business with NxStage."
NxStage's latest generation blood tubing set is the Streamline. Streamline features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes NxStage's patented LockSite(R) needleless access ports, which eliminate the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.
About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise(R)" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.
Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail B. Braun at email@example.com or visit B. Braun at www.bbraunusa.com.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's Streamline blood tubing sets and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Kristen K. Sheppard, Esq. VP, Investor Relations 978-332-5923 firstname.lastname@example.org
|SOURCE NxStage Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved